Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells, the cells in the body that normally fight infection. It is the most common cancer in children. Over the last several decades, advances in the treatment and supportive care of pediatric ALL have dramatically increased its 5-year survival rate to almost 90%. Despite these improvements, a considerable number of children with ALL continue to relapse following standardized treatment. Accurately diagnosing those patients who are high-risk (HR) for relapse and treating them with targeted therapies may greatly enhance their outcomes. To learn more about pediatric ALL and current treatment strategies, visit the NCI pediatric ALL website.

Last updated: March 15, 2017